Flype: Integrating Molecular and Pharmacogenomic Results to Enhance Oncology Patient Care in a Community-Based Academic Cancer Center
Simple Summary Integration of pharmacogenomic results with an oncology patient’s tumor molecular test results using Flype, a software developed at our institution, led to the identification of actionable genomic alterations to determine therapy options in patients with advanced cancers for whom standard therapies had been exhausted. Software enhancements to Flype supported the Kellogg Cancer Genomic Initiative, improved molecular test report turnaround times, while providing tools for molecular tumor board patient reviews. Integrating pharmacogenomic results into the molecular tumor board review led to improved therapeutic efficacy, such as avoiding the use of tamoxifen due to an increased risk of treatment failure and better pain management by detecting reduced CYP2D6 activation.